12/11/2026 - Campus Can Ruti, Projects, Research

A study in Catalonia finds a reduction in risk practices associated with injecting drug use, but warns of persistent social and health vulnerabilities

The REDAN study, coordinated by CEEISCAT-IGTP and involving 533 people who inject drugs in Catalonia, shows a decline in certain risk practices and improved access to sterile injecting equipment. However, high rates of HIV and hepatitis C infection, homelessness and experiences of violence highlight the need for a more comprehensive approach to harm reduction.

06/11/2026 - Campus Can Ruti, Conferences, Innovation, PATH

The PATH program brings together expertise across the Can Ruti Campus to drive progress in advanced therapies

The Program of Advanced Therapies (PATH) of IGTP held an event on 5 November to showcase capabilities across the Can Ruti Campus, foster collaboration between research groups, clinical professionals and companies, and address challenges in bringing advanced therapies into clinical practice.

05/11/2026 - Campus Can Ruti, Projects, Success Stories

La Marató de 3Cat funds three IGTP projects to improve cancer diagnosis and treatment

IGTP coordinates one of the selected projects and is involved in two others, focusing on the identification of biomarkers, treatment resistance and anti-tumour immune responses. Together, the three initiatives have received nearly €1.1 million in funding.

03/11/2026 - Research

New manufacturing platform facilitates the development of extracellular vesicle-based therapies

A study led by researchers from IGTP and BST has developed and validated a manufacturing platform for extracellular vesicles that meets pharmaceutical quality requirements, marking a key step towards their clinical application

30/10/2026 - Research

A rare case of Parkinson's disease reveals molecular changes in platelets during disease progression

An IGTP study, published in Movement Disorders, highlights the potential of platelets for investigating biomarkers of Parkinson's disease progression. Some of the changes were also observed in an independent cohort of 15 patients with early-onset sporadic Parkinson's disease.

27/10/2026 - Campus Can Ruti, CARE, Conferences

CARE expands its research community and strengthens links between research and clinical practice at its fourth Annual Meeting

IGTP’s CARE Program held its fourth Annual Meeting on 22 October. The event brought together researchers and healthcare professionals to share projects and research activities, meet the new groups joining the program and review the work carried out so far.

23/10/2026 - Campus Can Ruti, Research

HIPRA's COVID-19 vaccine generates a broad and long-lasting immune response to SARS-CoV-2 in adolescents, as demonstrated in adults

A clinical trial involving 240 adolescents aged 12 to 17 has shown that HIPRA's COVID-19 vaccine, BIMERVAX®, administered as a booster dose, induces a broad immune response against different SARS-CoV-2 variants, comparable to that observed in adults and sustained for at least one year. The study, published in Pediatrics, was led by IrsiCaixa, IGTP, VHIR and HIPRA as part of the European RBDCOV project.

21/10/2026 - Projects, Research

Air pollution and temperature variability are associated with higher blood glucose levels

A European study involving GCAT-IGTP has identified an association between greater exposure to air pollution, particularly PM10 particles, greater temperature variability and higher blood glucose levels in people without diabetes. The findings highlight the importance of studying environmental factors together and improving air quality in the context of climate change.

20/10/2026 - Campus Can Ruti, Conferences, Institutional

Artificial intelligence and biomarkers take centre stage at a new IGTP-EATRIS event

IGTP held a new event in collaboration with EATRIS, the European infrastructure for translational medicine, focusing this year on the role of artificial intelligence in biomarker research and precision medicine.

16/10/2026 - Campus Can Ruti, Innovation

Innomed visits IDNEO to learn about its capabilities in device development and digital technologies

The Innomed community visited IDNEO to learn about its capabilities in device development, digital technologies and MedTech solutions. The visit aimed to identify opportunities for collaboration between research teams and industry to advance healthcare innovation projects.